ClinicalTrials.gg
RecruitingNCT03704207Updated Jul 6, 2026

Utility of PCD Diagnostics to Improve Clinical Care

An interventional study of nNO testing in Primary Ciliary Dyskinesia, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jun 2017, registered Oct 2018).
  • Started Jun 2017; still recruiting 9 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.

Started
2017
the only one that year
No phase
5 of 28
5 open now
Registered
12th of 28
by date
Lead sponsor
2 of 28
Vanderbilt University Medical Center

Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is the only one that started in 2017, is one of 5 with no phase, and was the 12th registered.

Ciliary Motility Disorders

80 studies on the registry are indexed under Ciliary Motility Disorders; 27 are open to participants now.

Browse Ciliary Motility Disorders studies →

Open to participants now

9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Ciliary Motility Disorders studies recruiting now, 15 (71%) set no upper age limit and 3 (14%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ciliary Motility Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a study evaluating the utility of current Primary Ciliary Dyskinesia (PCD) diagnostic tests, including nasal nitric oxide testing.

Read the detailed description

This study is a prospective data collection of individuals referred to the investigators clinical center for considerations of PCD. Participants sign informed consent to have clinical information entered into a secure electronic database. As part of this study, participants may have nasal nitric oxide (nNO) testing performed. nNO testing is a research procedure, but it is a test with growing utility for making a diagnosis of PCD when performed in the right clinical setting.

03

Conditions studied

  • Primary Ciliary Dyskinesia
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Referred to center for PCD diagnosis considerations
  • Ability to perform study procedures
  • Age greater than 2 years of age

Exclusion criteria

Exclusion Criteria:

  • Age less than 2 years of age Inability to perform
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Nasal Nitric Oxide testing and collection of clinical data

    Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data

    Other: nNO testing

Interventions

  • OthernNO testing

    Collection of already performed clinical data and nNO testing

06

What researchers measure

Primary outcomes

  1. frequency of nNO tests performed

    number of tests

    Time frame: 3 years

  2. Frequency of genetic tests performed

    number of tests

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2017 (actual). Primary completion is estimated for Jun 2028, 132 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2018
First posted
Oct 12, 2018
StartActual
Jun 1, 2017
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03704207
Responsible party
Michael O'Connor (Assistant Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Oct 12, 2018
Start date
Jun 1, 2017
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Michael O'Connor, MD
Contact
michael.g.oconnor@vumc.org
615.343.7617

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion